Full-Spectrum EV Biomanufacturing Platform. A Category-Defining Opportunity.
We are conducting a pre-seed raise — selectively, and with a long-term lens. We are looking for strategic partners who understand what it takes to build a category-defining EV biomanufacturing platform — across modalities, markets, and geographies.
Round Stage
Pre-Seed
Status
Actively Raising
Investor Type
Strategic Only
Materials
Available Under NDA
Why EV Biomanufacturing?
Extracellular vesicles are poised to become a foundational modality in medicine. The bottleneck is not the science — it is the manufacturing infrastructure. That is what we are building.
Broad Platform Applicability
EVs are a powerful biological delivery system with demonstrated applicability across regenerative medicine, drug delivery, diagnostics, and consumer health. BioThera is not building a product — we are building a platform modality.
The Infrastructure Gap
Scalable, standardized EV manufacturing is the critical missing piece preventing the field from maturing. We are building that infrastructure with the rigor of a pharmaceutical company and the velocity of a startup.
Regulatory-Efficient Entry Point
Dermocosmetics provides a revenue-generating, regulatory-efficient path to validate the platform in the real world — generating commercial data, clinical evidence, and operational proof points before we expand horizontally.
Are You the Right Partner?
We are raising selectively. We want investors who are aligned on the long-term vision, bring more than capital, and understand the EV biomanufacturing opportunity. Complete the form below — we will follow up if there is alignment.
Prefer email? info@biotherasolutions.com
Investor Data Room
A dedicated investor portal with detailed materials — financials, IP overview, technical data packages, and team background — is available under NDA. Submit an inquiry above to request access.
This page is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction. Any offering of securities by BioThera Solutions Inc. will be conducted on a private placement basis pursuant to applicable exemptions, including the accredited investor exemption under National Instrument 45-106 Prospectus Exemptions (Ontario Securities Commission). Participation in any offering is restricted to accredited investors and other persons eligible under applicable securities law exemptions. Forward-looking statements reflect current expectations and are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially. This communication does not constitute investment advice. Past performance is not indicative of future results.